Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-151 in Advanced Solid Tumors
NCT05498597Phase 1Recruiting
- Sponsor
- Multitude Therapeutics
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of AMT-151 in solid tumor (advanced stage), ovarian cancer, endometrial cancer (EC) and 4 more, sponsored by Multitude Therapeutics. Primary endpoints: Maximum Tolerated Dose up to 24 months, Recommended Phase 2 Dose up to 24 months and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
AMT-151
03
Conditions
solid tumor (advanced stage)ovarian cancerendometrial cancer (EC)lung adenocarcinomatriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05498597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05498597.